Alcoholic liver disease (ALD) remains a major cause of morbidity and mortality worldwide. For example, the Veterans Administration Cooperative Studies reported that patients with cirrhosis and superimposed alcoholic hepatitis had a 4-year mortality of . 60%. Interactions between acetaldehyde, reactive oxygen and nitrogen species, inflammatory mediators and genetic factors appear to play prominent roles in the development of ALD. The cornerstone of therapy for ALD is lifestyle modification, including drinking and smoking cessation and losing weight, if appropriate. Nutrition intervention has been shown to play a positive role on both an inpatient and outpatient basis. Corticosteroids are effective in selected patients with alcoholic hepatitis and pentoxifylline appears to be a promising anti-inflammatory therapy. Some complementary and alternative medicine agents, such as milk thistle and S-adenosylmethionine, may be effective in alcoholic cirrhosis. Treatment of the complications of ALD can improve quality of life and, in some cases, decrease short-term mortality.
In Western countries, up to 50% of cases of end-stage liver disease have alcohol as a main aetiological factor. 1 In the USA, end-stage liver disease is the 9th leading cause of death. Between 1978 and 1988, alcohol was responsible for 44% of the deaths from cirrhosis in the USA. 2 The mortality from alcoholic cirrhosis is higher than that of non-alcoholic cirrhosis and the survival rate at 5 and 10 years is only 23 and 7%, respectively, in some studies. 3 Thus, the mortality of this liver disease is more than that of many major forms of cancer, such as breast, colon and prostate. 4 This chapter will review three major aspects of alcoholic liver disease (ALD): (i) diagnosis, (ii) aetiology and (iii) treatment.
DIAGNOSIS OF ALD Risk factors
In order to develop liver disease, a 'threshold' regarding daily amount and length of time of alcohol intake has to be exceeded. Daily intake of alcohol for 10 -12 years with doses in excess of 40 -80 g/day for males and of 20 -40 g/day for females are generally needed to cause ALD. 5 -8 Because alcoholic beverages have different alcohol content, it is important to convert 'usual serving' sizes to g of alcohol. Thus, 12 oz of beer (5% v/v alcohol) provides 13.85 g of alcohol versus 4 oz of wine (12% v/v alcohol), which provides 10.7 g, whereas 2 oz of fortified wine (20% v/v alcohol) and 1 oz of 'spirits' (40% v/v alcohol) provide 8.9 g of alcohol each. Thus, daily drinking of 3 -6 cans (12 oz each) of beer/day for males or 1.5 -3 cans of beer/day for females for 10 years or longer can cause ALD.
Despite the need for a threshold with respect to dose and length of time for the development of ALD, there is not a particular amount of alcohol that will predictably cause ALD. Among heavy, long-term alcohol drinkers, 90 -100% develop fatty liver but only 10 -35% develop alcoholic hepatitis and 8-20% will develop alcoholic cirrhosis. 9 Thus, alcohol probably works as a 'potential hepatotoxin', with the development of liver disease depending on the balance of host attributes and co-existing external factors, such as gender, polymorphism of alcohol-metabolizing enzymes, immunological factors, exposures to other substances/drugs, hepatic viral infections, nutritional deficiencies, obesity, etc.
Diagnosis
The diagnosis of ALD is established with a history of habitual alcohol intake of sufficient length and intensity together with physical signs and/or laboratory evidence of liver disease. The diagnosis can be made difficult because patients frequently minimize or deny alcohol abuse. In addition, physical examination findings may be absent and laboratory abnormalities may be non-specific. 10 -12 The severity of injury spans the spectrum, from fatty liver (steatosis) to steatohepatitis to cirrhosis. Cirrhosis and steatohepatitis often co-exist. The tool most frequently used to assess alcohol dependency is the CAGE questionnaire, which explores the lifetime occurrence of, or need for, Cutting down on drinking, Annoyance when others express concern about the amount of drinking, Guilt about drinking and need of alcohol as an Eye opener. Two positive answers indicate alcohol dependency with a sensitivity of more than 70% and specificity of more than 90%. 13, 14 An important caveat is that alcohol dependency is not a pre-requirement for the development of ALD because some people are exquisitely sensitive to the effects of alcohol.
Ambulatory patients with alcoholic fatty liver are usually asymptomatic 15 but 70% of hospitalized patients with steatosis have hepatomegaly and one-third have laboratory abnormalities. 16 Patients with alcoholic steatohepatitis may be asymptomatic, have only hepatomegaly, or have a full-blown picture of alcoholic hepatitis with tender hepatomegaly, jaundice, fever, ascites, hepatic encephalopathy, anorexia, malaise and even leukaemoid reactions and hepatorenal syndrome. Portal hypertension may be present, even in the absence of cirrhosis. Once a patient has alcoholic hepatitis, the probability of developing cirrhosis is 10 -20% per year, and up to 70% will eventually develop cirrhosis. 17 The patients at higher risk for the development of cirrhosis are those who continue drinking, have severe alcoholic hepatitis and who are female. 18 Some patients who abstain may still develop cirrhosis, but others will have complete clinical and histological recovery. We do not know if, in older studies, other poorlyrecognized liver disorders at that time (hepatitis C, non-alcoholic fatty liver disease, etc) were contributing factors in the patients who had progressive liver disease despite alcohol abstinence.
Patients with well-compensated alcoholic cirrhosis may be asymptomatic and have normal physical examinations. Alcoholic steatosis or steatohepatitis are often coexistent and the patient may have hepatomegaly and/or splenomegaly. In those cirrhotics with severe alcoholic hepatitis, hepatomegaly and/or splenomegaly may dominate the clinical features; in other patients, the signs and symptoms of portal hypertension may dominate. As the disease advances, the liver decreases in size, the left hepatic lobe becomes more prominent and the entire liver has a hard and nodular consistency. Splenomegaly of varying degree is frequent. In decompensated disease, patients have muscle wasting, ascites and venous collateral circulation. Spider angiomata, palmar erythema and Dupuytren's palmar contractures are common. Parotid and lacrimal gland enlargement is often seen. Some patients with severe hypoalbuminaemia have Muercke's nails or have white nails. Clubbing of the fingers may be found in patients who have meaningful arterio-venous pulmonary shunting. Oesophageal varices, gastric varices and portal hypertensive gastropathy are frequently found during endoscopy. When hepatic encephalopathy is present, patients have slow reaction time and may have asterixis. None of the physical signs and symptoms are pathognomonic for ALD.
Laboratory data
For habitual alcohol consumption (more than 50 g/day with liver injury), aspartate transaminase (AST) is more sensitive (50% sensitivity) than alanise transaminase (ALT) (35% sensitivity) but ALT elevation is a little more specific (86% specificity) than AST elevation (82% specificity). 19 Almost all patients will have elevation of AST . ALT with both below 300 IU/ml. 20 -22 When the AST:ALT ratio is greater than two, the most likely diagnosis is ALD; in some studies, more than 80% of patients reach this ratio. 23, 24 Elevation of g glutamyltransferase (GGT) is more sensitive (70%) but less specific (65 -80%) than elevation of AST or ALT for excessive alcohol consumption. Because GGT is ubiquitous in many organs and drugs that induce the microsomal enzymes cause GGTelevation, the specificity of GGTelevation is limited. In addition, GGT is increased in most forms of liver injury. Because alcohol causes mitochondrial damage, mitochondrial AST (mAST) is a very sensitive marker of alcohol consumption. However, this test is not routinely used in clinical care.
Chronic alcohol consumption is also often associated with hypertriglyceridaemia, hyperurecaemia, hypokalaemia and hypomagnesaemia, as well as elevated mean corpuscular erythrocyte volume (MCV). 25 Hyperuricaemia and hypertriglyceridaemia often normalize with abstinence and hypokalaemia normalizes with adequate replacement. Elevated MCV is often found in persons ingesting more than 50 gm alcohol/day, with a sensitivity of 27 -52% and specificity of 85 -90%. 14, 19, 26 Carbohydrate-deficient transferrin is frequently used to detect current or recent alcohol abuse, especially in excess of 60 g/day. 27, 28 However, there are no ideal tests to identify continuing ethanol intake.
Leukocytosis and thrombocytopaenia are common in alcoholic hepatitis. Occasionally patients have leukaemoid reactions with counts of 100 000 white blood cells (WBC)/mm 3 in the absence of infection. Thrombocytopaenia may be transitory, but in patients with concomitant cirrhosis, it is persistent. Elevation of bilirubin, prolongation of prothrombin time (PT) and hypoalbuminaemia are markers of severe alcoholic hepatitis and/or cirrhosis. The most commonly used prognostic index in alcoholic hepatitis is the 'Maddrey's Discriminant Function', which is calculated using the equation: 4.6 £ (PT patient 2 PT control) þ total bilirubin (mg/dl). If this value exceeds 32, the mortality during the current hospitalization is in excess of 50%. 29, 30 There is also evidence that serum concentrations of tumour necrosis factor-a (TNF-a), interleukin-6 (IL-6) and interleukin-8 (IL-8) correlate with mortality in patients with alcoholic hepatitis 31 , but levels of these cytokines are not used in routine clinical practice.
Histology
Clinical diagnosis of ALD is sensitive (91%) and specific (96%) with a positive predictive value of 88% and negative predictive rate of 97%, at least in an educated population. 32 In another study, clinical diagnosis was 79% sensitive but 98% specific. 33 Because clinical diagnosis is very specific and has a high positive predictive value, liver biopsy is rarely used just to establish the diagnosis. Its main use is to clarify atypical cases, to better define the alcohol contribution in patients with possible co-existing conditions and to stage the severity of liver disease.
Most persons who habitually drink more than 60 g/day of alcohol will develop fatty liver in the centrilobular or perivenular region. Subjects who have severe mixed micro/macrovesicular pattern, and/or giant mitochondria are more likely to develop fibrosis and evolve to cirrhosis. 34, 35 Alcoholic hepatitis is characterized by ballooning degeneration of hepatocytes with polymorphonuclear cell infiltration (97%), moderate to severe fatty infiltration (82%), Mallory bodies (76%), sclerosing hyaline necrosis (68%) and increased fibrosis (54%) with perivenular fibrosis (19%). 36 Of interest, in contrast with alcoholic fatty liver, the presence of megamitochondria in alcoholic hepatitis appears to improve its prognosis.
MECHANISMS OF LIVER INJURY
The following will be reviewed: (i) alcohol metabolism, (ii) oxidative stress, (iii) cytokines/inflammatory mediators, (iv) genetic factors and the interactions of these factors. There are multiple potential overlapping mechanisms for liver injury in ALD (Figure 1 ).
Alcohol metabolism
Toxic by-products of alcohol metabolism Toxic by-products of alcohol were an initially popular concept. In the liver, there appear to be three major enzyme systems that mediate the initiation of ethanol metabolism (oxidation). While the dominant system is clearly alcohol dehydrogenases (ADH), the cytochrome P450 systems (predominantly CYP2E1) and catalases also play important roles. All three of these biochemical pathways produce acetaldehyde as their product. While acetaldehyde is subsequently oxidized to acetate by aldehyde dehydrogenases (ALDH), the kinetics of this reaction are sufficiently slow to allow the accumulation of detectable increases in acetaldehyde in humans consuming alcohol. A number of Mechanisms by which ethanol consumption may lead to liver damage. Ethanol causes a number of physiological and biochemical changes to liver that may lead to the initiation and progression of alcoholic liver disease (ALD). These include the following. Alcohol metabolism, via the formation of toxic byproducts (e.g. acetaldehyde), increasing the cellular redox state and induction of enzymes that metabolize ethanol (e.g. CYP2E1). Inflammation coupled with priming of these immune cells and an increase in proinflammatory cytokines and chemokines. Sensitization of hepatic cells, via alteration of intracellular signalling, depletion of energy reserves and an increased response to external stimuli (e.g. cytokines/chemokines) alters/enhances the response of the cells during the course of alcohol administration. Reactive oxygen species/reactive nitrogen species (ROS/RNS) formation, via electron leakage from enzyme systems (e.g. mitochondria and CYP2E1), inflammatory cells and by decreased degradation of oxidatively-modified proteins is proposed to play a key role in mediating the effects of ethanol. These events are not mutually exclusive and tend to enhance the effects of the other pathways. The net result is a vicious cycle of damage and progression in the disease. Polymorphisms in key genes involved in these events are also thought to cause the sensitivity of some individuals to chronic alcohol abuse.
the systemic toxic effects of ethanol abuse (e.g. flushing, headaches and nausea) are mediated, at least in part, by the direct or indirect effects of elevated acetaldehyde levels. At the more local level, it is proposed that acetaldehyde may also play an aetiological role in ALD. 38 For example, acetaldehyde can form adducts with reactive residues on proteins or small molecules (e.g. cysteines). These chemical modifications can alter and/or interfere with normal biological processes and be directly toxic to the cell. Modified biological molecules may also stimulate the host's immune response and cause an autoimmune-like disease. Antibodies against such oxidatively modified proteins have been reported in both humans and animal models of ALD. 39, 40 For example, a hybrid adduct of malondialdehyde and acetaldehyde (MMA) unique to alcohol exposure has been shown to induce an immune response both in human alcoholics and in animal models of ALD. 41 An indirect mechanism by which alcohol metabolism may contribute to ALD is the induction of the cytochrome P450, CYP2E1. The co-localization of CYP2E1 in the hepatic lobule regions of liver damage after alcohol consumption led to the hypothesis that CYP2E1 plays a causal role in ALD. Inhibitors of CYP2E1 partially blocked hepatic pathology caused by ethanol in animal models 42 , supporting this hypothesis. While the mechanism(s) by which CYP2E1 induction may play a role in ALD are unclear, it is proposed that this enzyme is a source of oxidative stress (see below). For example, CYP2E1 has been shown to be loosely coupled with cytochrome reductase, leaking electrons to oxygen to form O 2 z2 or to catalyze lipid peroxidation. 43 However, since cultured hepatocytes have relatively low CYP2E1 activity, these questions were difficult to evaluate in the intact cell. To address this problem, HepG2 cells that overexpress CYP2E1 were developed. The work to date with these cells has supported the hypothesis that CYP2E1 is involved in hepatocyte damage due to alcohol. 44 However, mice lacking CYP2E1 developed liver injury analogous to their wild-type counterparts. 45 It has been suggested that other isoforms of CYP (e.g. CYP4A) may play a compensatory role in the initiation of early alcohol-induced liver injury in the absence of CYP2E1 in the knockouts. 46 Nevertheless, it appears that CYP2E1 is not required for the initiation of alcohol-induced liver injury in mice. This observation does not preclude a role for CYP2E1 in later stages of disease progression in mice or in other species. Much work remains to be done to address these issues.
Biochemical effects of alcohol metabolism
In addition to forming cytotoxic byproducts, ethanol metabolism can alter the cellular redox state, which can indirectly be involved in liver damage. Specifically, the oxidation of ethanol to acetaldehyde by ADH and its subsequent oxidation to acetate by ALDH utilizes NAD þ as an electron acceptor, causing a shift in the NADH:NAD þ ratio to a more reduced state. This change in the redox state can impair normal carbohydrate and lipid metabolism, which has multiple effects, including decreasing the supply of ATP to the cell. 47 The increase in the reduced state of pyridine nucleotides has also been proposed as being involved in the accumulation of lipids during alcohol ingestion (steatosis), which appears to be critical for the progression to more severe damage in the disease. 48 
Oxidative stress
Reactive oxygen and nitrogen intermediates (ROS and RNS, respectively) can be products of normal cellular metabolism and have beneficial effects (e.g. cytotoxicity against invading bacteria). However, since these molecules also have the potential to damage normal tissue, the balance between pro-oxidants and antioxidants is critical for the survival and function of aerobic organisms. If the balance is tipped in favour of overproduction of these species, oxidative stress can occur. Oxidative stress has been proposed to be critically involved in ALD. 49, 50 Oxidative stress associated with clinical ALD is most probably not due to an increase in pro-oxidant formation alone. Alcoholics replace up to 50% of their total daily calories with ethanol 51 , leading to nutritional deficiencies that can be further complicated by nutrient malabsorption. 52 The net effect is that alcoholics often have lower levels of key dietary antioxidant molecules (see Lieber 47 for a review) and a decreased overall antioxidant status. Therefore, oxidative stress in ALD is most probably mediated by both an increase in pro-oxidant production and a decrease in antioxidant defences.
In support of the hypothesis that oxidative stress is involved in ALD, numerous antioxidants have been shown to protect against the damaging effects of ethanol in both in vitro and in vivo models of ALD. 53 -55 Although important advances have been made in understanding the role of pro-oxidants in experimental alcohol-induced liver injury, this work has yet to translate into an accepted antioxidant therapy for ALD. With a better understanding of the mechanisms by which oxidative stress leads to liver damage during alcohol exposure, antioxidant therapies that are targeted to the specific cellular/molecular effects of ethanol may be applied in the clinic with potentially greater success.
ROS: a role for superoxide

Superoxide (O 2
z2 ) can come from many sources within the cell, including direct production from enzymes (e.g. xanthine oxidase and NA(D)PH oxidases), as well as electron leakage from enzyme systems not specifically designed to produce the radical (e.g. mitochondria and CYP2E1). Support for the role of O 2 z2 in ALD comes predominantly from correlations between injury and levels of superoxide dismutase (SOD), an enzyme that catalytically reduces O 2 z2 to hydrogen peroxide (H 2 O 2 ). 56 For example, levels of SOD correlated inversely with pathological changes in the enteral alcohol model of experimental ALD. 57 Furthermore, exogenous SOD has shown protective/antioxidant effects in both in vitro and in vivo models of alcohol exposure. Furthermore, gene delivery of either cytosolic Cu/Zn-SOD or mitochondrial Mn-SOD by adenoviral vectors has also been shown to prevent alcohol-induced liver injury in rats in the enteral model of alcohol injury. 58, 59 While there is clear experimental evidence that pro-oxidant formation is dependent on the production of O 2 z2 , this radical is itself not a potent oxidant. O 2 z2 can alternatively react through catalytic pathways in the cell to form more potent oxidants, such as the hydroxyl radical (OH; the Fenton reaction) 60 and hypochlorous acid (HOCl). 61 An additional pathway for O 2 z2 -dependent oxidative stress involves the enzyme-independent reaction of O 2 z2 with NO z to form peroxynitrite (ONOO 2 ), another strong oxidizing and nitrating species. 62, 63 All of the above-mentioned pathways form pro-oxidants with the redox potential to lead to the formation of the a-hydroxyethyl radical. Therefore, O 2 z2 can be considered to be a key 'starting point' of oxidative stress during alcohol exposure.
RNS: a role for nitric oxide
Like O 2 z2 for ROS, it is likely that NO z serves as the 'parent' molecule for other RNS. Unlike O 2 z2 , NO z has pleotropic effects that obscure whether it predominantly plays a protective or a damaging role in ALD. 64 For example, it is well known that the disregulation of vascular tone after acute alcohol intake and in alcoholic cirrhosis is mediated, in part, by a decrease in NO z production. 65, 66 It has also been shown that NO z is anti-apoptotic in hepatocytes and is required for normal liver regeneration. 67, 68 However, high levels of NO z can also play a potentially damaging role in ALD by the production of RNS, such as ONOO 2 . RNS derived from NO z can cause nitration reactions (e.g. 3-nitrotyrosine formation) and nitrosation reactions (e.g. nitrosothiol formation), as well as oxidation reactions during alcohol exposure. Thus, NO z may play a dual role in ALD, mediating both protective effects and tissue damage by overproduction of RNS. Which of these events predominates in vivo may depend on the cell type, NOS isoform and stage of disease studied.
Alcohol-induced modifications in cellular redox balance independent of pro-oxidant formation Alcohol also causes modifications to the cell that can lead to oxidative stress independent of increased pro-oxidant production per se. Lower antioxidant levels in alcoholics due to the nutritional deficiencies are an example. The mobilization of free iron caused by alcohol can also lead to an increase in transition-metal catalysis to potent oxidants (e.g. the Fenton reaction). Indeed, experiments have shown that iron supplementation enhances damage due to alcohol. 44, 69 Another example is the inhibition by alcohol of the 26 S proteosome in hepatocytes. 42 This critical complex is responsible for degrading oxidatively modified proteins; therefore, its inhibition leads to the accumulation of these damaged proteins, possibly even in the absence of a real increase in pro-oxidants. 70 Finally, there exist a host of proteins and systems involved in the 'antioxidant network'. This family does not directly intercept pro-oxidants, but they serve instead as ancillary reductants and maintain the catalytic activity of antioxidant proteins or small molecules. These reactions require cellular energy to maintain such cycles. The depletion by ethanol of both cytosolic and mitochondrial energy supplies (see above) can thus indirectly impair cellular antioxidant defences.
How are oxidants involved in alcoholic liver injury?
One mechanism by which oxidative stress is proposed to cause cellular injury is by chemical modification of biological molecules, which can alter and/or interfere with normal processes within the cell. Also, antibodies against oxidatively modified proteins have been shown to be produced in both humans and animal models of ALD. 39, 41 These antibodies have the potential to stimulate an autoimmune-like disease in the liver. It is now clear that pro-oxidants can also mediate and/or amplify their signal by modifying signalling cascades within the cell. Many recent reviews have focused on the role of signalling cascades in damage due to oxidative stress. 71274 Oxidant sensitive signalling cascades include small molecules (e.g. intracellular Ca þ þ ) 75 , stress-activated protein kinases (SAPK), (e.g. C-Jun N-terminal kinase (JNK), endoplasmic reticulum kinase 1 and /or 2 (ERK 1/2) and p38) 76 , transcription factors (e.g. activator protein-1 (AP-1), hypoxia-inducible factor-1 (HIF-1) and nuclear factor which binds to the kB site on DNA (NFkB)) 77 , and modulators of apoptosis signalling (e.g. caspases, Bad and Bcl-2).
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Ethanol has been shown to modulate the signal of many of these cascades in vitro and/ or in experimental ALD; however, whether or not these effects are mediated by oxidative stress per se is often unclear.
Cytokines and inflammatory mediators
Priming and sensitization of inflammation during ALD A key concept in alcoholic liver injury is priming and sensitization. As mentioned above, the natural history of ALD is characterized by chronic inflammation in the liver. This activation of the immune response can be at least partially attributed to increased levels of activators of this response, such as lipopolysaccharides (LPS). 79, 80 However, the elevated levels of LPS found in alcoholics and in experimental ALD are relatively low compared to those found in endotoxaemia. Furthermore, damage to liver caused by alcohol cannot be mimicked by chronic low-dose LPS in the absence of ethanol. 81 Instead, inflammatory cells appear to be primed to activation by alcohol administration. For example, peripheral blood monocytes obtained from patients with alcoholic hepatitis spontaneously produce proinflammatory mediators (e.g. TNF-a) and they produce more of these mediators in response to LPS than do control monocytes.
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Other cytokines and chemokines that have been shown to be elevated in ALD patients include IL-6 83 , IL-8 84 , monocyte chemoattractant protein 1 (MCP-1) 85 , and macrophage inflammatory protein 1 (MIP-1). 86 In addition to cytokine/chemokine production, there are a host of other mediators of inflammation that are increased in ALD, such as adhesion molecule expression, ROS/RNS (see above), and cytokine receptors (e.g. tumour necrosis factor receptor 1 (TNFR1)) to mention only a few. Moreover, a number of the systemic effects of ALD (e.g. muscle wasting, increased gut permeability and fever) are thought to be mediated by elevated levels of proinflammatory mediators.
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In addition to priming inflammatory cells, liver cells appear to be sensitized to inflammatory stimuli by alcohol administration. For example, although TNF-a is normally pro-proliferative in hepatocytes isolated from naïve animals, it is proapoptotic in cells isolated from ethanol-treated animals. 88 Furthermore, HepG2 cells overexpressing CYP2E1 are more sensitive to TNF-a-induced cell killing after exposure to alcohol. 89, 90 This appears to be mediated through the cellular 'death domain' pathways. 90 Other cell types (e.g. stellate cells) also appear to be primed/ sensitized during alcohol administration. 91, 92 The concept of priming and sensitization also implies that there may be a series of sequential events in the progression of liver injury during alcohol exposure. Specifically, the priming of inflammatory cells by ethanol leads to a more robust cell-killing response that is exacerbated in sensitized hepatocytes. This pattern explains why blocking the activation of Kupffer cells or employing knockouts with an impaired Kupffer cell response protects against damage in hepatocytes. For example, knocking out the LPS serum carrier protein, LPS binding protein (LBP), blocked liver damage but did not prevent induction of CYP2E1. 93 Such cell-to-cell signalling is also proposed to underlie the mechanism(s) by which some proteins appear to have both damaging and protective roles in ALD. For example, the transcription factor NF k B is a key mediator in the inflammatory response in Kupffer cells by upregulating proinflammatory genes (e.g. TNF-a). However, NFkB inhibition causes apoptosis after addition of TNF-a or a membrane receptor mediating apoptosis (Fas) to cultured hepatocytes. 94, 95 When rats were transfected with adenoviral vectors containing the inhibitor of kB (IkB) superrepressor, liver damage due to enteral alcohol was prevented. 96 Furthermore, the production of TNF-a in the liver was also blunted. It is, therefore, likely that under these conditions, the potentially damaging/proinflammatory effects of NFkB activation, such as TNF-a production in Kupffer cells, precede any protective/anti-apoptotic effects in the hepatocyte.
Effects of proinflammatory cytokines in ALD beyond inflammation
An interesting observation regarding antioxidants and knockout mice in studies of experimental ALD is that many of these conditions blunt the steatosis caused by alcohol. 53 -55,58,59,97 As mentioned above, steatosis due to alcohol is generally considered to be the result of NADH redox inhibition of mitochondrial b-oxidation caused by alcohol metabolism. While redox changes are likely to be necessary for alcohol-induced steatosis, the data obtained with antioxidants bring into question whether this redox shift is sufficient in and of itself. Specifically, none of the conditions mentioned above had any apparent effect on alcohol metabolism. A factor that these studies have in common is that the increase in cytokine (e.g. TNF-a) production caused by alcohol was blunted. TNF-a (and other cytokines) can indeed influence lipid metabolism both in the liver and the periphery (see Pessayre et al 98 , for a review). For example, TNF-a increases free fatty acid release from adipocytes in the periphery 99 , increases lipogenesis in hepatocytes 100 , and inhibits b-oxidation of fatty acids. 101 Other cytokines induced by alcohol (e.g. IL-1 and IL-6) may also impair transport and secretion of triglycerides. 102 The net consequence during alcohol exposure is that cytokines increase the supply of fatty acids to the liver while simultaneously impairing the ability of the hepatocytes to metabolize and secrete them. In support of this hypothesis, TNFR1 knockout mice are protected against alcohol-induced fat accumulation in experimental ALD. 103 It is proposed that these effects work in tandem with alcohol-induced shifts in the NADH redox state to lead to steatosis.
Genetic polymorphisms and the risk of ALD
It is clear that the risk for the development of ALD increases with the time-and dosedependent consumption of alcohol. 104 However, even in populations that consume high levels of ethanol (e.g. . 80 g/day), only a fraction of individuals develop severe forms of the disease (e.g. alcoholic hepatitis and cirrhosis). Even when other risk factors (e.g. diet composition, concomitant hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, etc) are taken into account, there is no combination of environmental risk that leads to a 100% incidence of the disease. Furthermore, some individuals develop ALD while consuming much less alcohol. For these reasons, it has long been proposed that in addition to environmental risk factors, there are genetic risk factors that increase the risk for the development of ALD. 105 It is now clear that many gene products are polymorphic in the human population; polymorphisms in these genes give rise to structural and functional variations in the resultant proteins. It has been proposed that polymorphisms in key genes hypothesized to be involved in the development of ALD may be the basis of the apparent genetic risk for the development of the disease. Indeed, many of the above-described pathways thought to be involved in ALD are known to be polymorphic. For example, ethanolmetabolizing systems (e.g. ADH, ALDH and CYP2E1) have been shown to be polymorphic. 106 Indeed it is now clear that polymorphisms in ALDH gene products are responsible for alcohol sensitivity, especially in Asian populations, and that these individuals develop ALD while consuming less alcohol. 107 ROS/RNS formation and damage are also clear candidates, but have yet to be clearly shown in large casecontrolled studies. As mentioned above, iron catalysis of oxidative stress may be critical in ALD; indeed, there is a strong link between disregulated iron homeostasis (e.g. haemochromatosis) and alcohol-induced liver disease. 108 Lastly, polymorphisms in proinflammatory (e.g. TNF-a) and anti-inflammatory (e.g. IL-10) cytokines have also been linked to increased risk for ALD. 109, 110 It should be mentioned that, as with environmental risk factors, there is no genetic variation identified thus far that leads to a 100% incidence of ALD in individuals who drink. Instead it is likely that multiple environmental and genetic factors combine to determine the risk of the individual. The goal of future work is to better delineate these factors.
THERAPY FOR ALCOHOLIC LIVER DISEASE
We have reviewed the major advances that have been made in our understanding of mechanisms of alcohol-induced liver injury, and these concepts are being translated into clinical trials. Moreover, we are now in a position to better understand some of the mechanisms of actions of some traditionally-used therapies for ALD, ranging from steroids to antioxidant therapy. This section on therapy will touch on the importance of: (i) life-style change, including abstinence; (ii) nutrition; (iii) drug therapy (conventional and alternative therapies) and (iv) the role of liver transplantation (Table 1) .
Life-style change
Abstinence from alcohol is vital in order to prevent further ongoing liver injury, fibrosis and possibly hepatocellular carcinoma. Abstinence causes total resolution of alcoholic steatosis. There are limited studies evaluating the effects of abstinence from alcohol on the progression of ALD and these are retrospective, non-randomized trials. However, virtually all studies show beneficial effects of abstinence. Early studies from Klatskin's programme showed that, in particular, patients with jaundice or ascites benefited from abstinence. 111 Merkel et al 112 in a recent small series of patients having alcoholic cirrhosis who were followed for 4 years or until death, showed that the cumulative probability of survival was 87% in persistent abstainers and only 55% in persistent drinkers. Patients with compensated or decompensated cirrhosis benefit from abstinence. Moreover, unpublished data from recent Veterans Health Administration (VA) Co-operative Studies suggest that reducing, but not stopping, ethanol consumption also improves projected survival in ALD (Drs C. Lieber and T. Morgan, pers. comm.). Thus, abstinence, or a major reduction in drinking, should be encouraged in all patients with ALD. Newer agents to improve abstinence, such as Naltrexone and Acamprosate, have been shown to have efficacy in some chronic alcoholics; however, there are no large multicentre studies evaluating these drugs in patients with ALD.
Many subjects who drink alcohol also smoke cigarettes. Smoking cigarettes has been shown in European studies to increase the rate of progression of fibrosis in ALD. 113, 114 Moreover, hepatitis C patients who drink also have accelerated disease progression if they smoke cigarettes. 115 Cigarette smoking causes oxidative stress and this may be another mechanism for the observed accelerated liver disease in smokers.
Obesity is associated with the development of fatty liver and non-alcoholic steatohepatitis (NASH). Body mass index (BMI) has been shown to be an independent risk factor for the development of ALD. 116 Thus, similar to many other gastrointestinal disorders (e.g. gastro-oesophageal reflux disease), the initial approach to ALD is lifestyle modification related to issues of alcohol consumption, cigarette smoking and obesity.
Nutrition therapy
Malnutrition is prevalent in liver disease, especially in the more severe forms of chronic liver disease. Probably the most extensive studies of nutritional status in patients with liver disease are large studies in the VA Cooperative Studies Program dealing with patients having alcoholic hepatitis. 117 The first of these studies 118 demonstrated that virtually every patient with alcoholic hepatitis had some degree of malnutrition. Patients had a mean alcohol consumption of 228 g/day (with almost 50% of energy intake coming from alcohol). The severity of liver disease generally correlated with the severity of malnutrition. Similar data were generated in a follow-up VA study on alcoholic hepatitis. 119 In both of these studies, patients were given a balanced 2500-kcal hospital diet, monitored carefully by a dietitian, and were encouraged to consume the diet. In the second study, patients in the therapy arm of the protocol also received an enteral nutritional support product high in branched-chain amino acids (BCAAs), as well as the anabolic steroid oxandrolone (80 mg/day). Patients were not fed by tube if voluntary oral intake was inadequate in either study (probably a study design flaw, in retrospect). Voluntary oral food intake correlated in a stepwise fashion with 6-month mortality data. Thus, patients who voluntarily consumed . 3000 kcal/day had virtually no mortality, whereas those consuming , 1000 kcal/day had . 80% 6-month mortality (Figure 2 ). 117 Moreover, the degree of malnutrition correlated with the development of serious complications such as encephalopathy, ascites and hepatorenal syndrome. 121 demonstrated that outpatients taking an enteral nutritional support product (1000 kcal, 34 g protein) had significantly improved protein intake and significantly fewer hospitalizations. These same investigators subsequently gave an enteral supplement to outpatients with alcoholic cirrhosis and observed an improvement in nutritional status and immune function. 122 In the VA Cooperative Study No. 275 on nutritional support in ALD using both an anabolic steroid and an enteral nutritional supplement, improved mortality was seen with the combination of oxandrolone plus supplement in patients who had moderate protein -energy malnutrition. 117 Those with severe malnutrition did not significantly benefit from therapy, possibly because their malnutrition was so advanced that no intervention, including nutrition, could help. Studies by Kearns et al 123 showed that patients with ALD hospitalized for treatment and given an enteral nutritional supplement via tube feeding had significantly improved serum bilirubin levels and liver function as assessed by anti-pyrine clearance. Moreover, a major randomized study of enteral nutrition versus steroids in patients with alcoholic hepatitis showed similar overall initial outcomes and fewer long term infections in the nutrition group. 124 Thus, traditional nutritional supplementation clearly improves nutritional status and, in some instances, hepatic function and other outcome indicators in alcoholic hepatitis/cirrhosis.
Drug therapy (conventional and alternative therapies)
Although ALD remains a major cause of morbidity and mortality in the USA, there is no Food and Drug Administration (FDA) approved therapy for either alcoholic cirrhosis or alcoholic hepatitis. However, there are several drugs that have been widely used. We will discuss only therapies available in the USA for which there generally have been large randomized human studies.
Propylthiouracil
Chronic alcohol feeding in experimental animals produces a hypermetabolic state with increased oxygen consumption. This may lead to relative hypoxia, especially in the central lobular area, or Zone 3, of the liver. Propylthiouracil (PTU) has been postulated to attenuate this hypermetabolic state, to function as an anti-oxidant and to improve portal blood flow. This prompted a long-term study of PTU therapy by Orrego and Energy intake (kcal/day) co-workers in over 300 patients with a variety of types of liver disease, including ALD. 125 In the total study population, mortality was reduced by nearly 50% in patients receiving PTU. 125 A recent Cochrane review evaluated PTU therapy for ALD, including alcoholic steatosis, alcoholic fibrosis, alcoholic hepatitis and/or cirrhosis. 126 Combining the results of six randomized clinical trials, which included 710 patients, no significant effects of PTU versus placebo on mortality or liver-related mortality, complications of liver disease, or liver histology were shown. 126 The negative results of this review, as well as hepatologists' natural aversion to render metabolically-compromised patients hypothyroid, limit enthusiasm for PTU in ALD.
Colchicine
Colchicine has been suggested as a treatment for ALD because of its anti-fibrotic effects. It has many potential therapeutic mechanisms of action including inhibition of collagen production, enhancement of collagenase activity and anti-inflammatory functions. Initial positive studies by Kershenobich et al 127 led to a large VA Cooperative Study evaluating colchicine therapy in alcoholic cirrhosis that has recently been completed. Results showed no beneficial effect on either overall mortality or liverrelated mortality. 128 A recent smaller study from Europe also showed no beneficial effects of colchicine. 129 Thus, despite initial enthusiasm and biochemical rationale for use of this drug, it does not appear to be effective in ALD.
Corticosteroids
Corticosteroids have been the most extensively-studied form of therapy for alcoholic hepatitis, but their role remains limited. 130 The rationale for steroid use is to decrease the immune response and proinflammatory cytokine response. Most randomized studies have supported the use of corticosteroids in moderate/severe alcoholic hepatitis, but the large multicentre VA study headed by Mendenhall yielded negative results. 30, 131 Most meta-analyses support the use of steroids for severe acute alcoholic hepatitis including the most recent study. 132 This study reported significantly improved survival at 28 days (85% versus 65%) in severely ill alcoholic hepatitis patients having a discriminant function (DF) of . 32. This survival advantage may extend to 1 year, but not 2. Independent prognostic factors associated with death at 28 days in this metaanalysis were steroid treatment, age and creatinine. It is important to note that the patients studied were highly selected and infections (e.g. spontaneous bacterial peritonitis), gastro-intestinal bleeding and many other common complications were exclusions for entry into these studies. Most investigators agree that if corticosteroids are to be used, they should be reserved for those with relatively severe liver disease (DF . 32), and possibly those with hepatic encephalopathy. Steroids have welldocumented side effects, including enhancing the risk of infection, which is already substantial in patients with alcoholic hepatitis. Thus, a major disadvantage to corticosteroids is their lack of applicability in many patients with alcoholic hepatitis.
Pentoxifylline
Pentoxifylline (PTX) is a non-selective phosphodiesterase inhibitor that increases intracellular concentrations of adenosine 3 0 ,5 0 -cyclic monophosphate (cAMP) and guanosine 3 0 ,5 0 -cyclic monophosphate (cGMP) and decreases production of proinflammatory chemokines/cytokines including TNF. Akriviadis et al 133 from the University of Southern California Liver Unit performed a prospective, randomized, double-blind clinical trial of PTX in severe alcoholic hepatitis (DF . 32). Forty-nine patients received 400 mg of PTX orally 3 times daily and 52 received placebo (vitamin B 12 ) for 4 weeks. PTX treatment improved survival. Twelve PTX patients died (24.5%) compared with 24 (46%) placebo patients. PTX also decreased hepatorenal syndrome as a cause of death. Six out of the 12 (50%) PTX-treated patients who died did so of renal failure compared with 22 out of the 24 (92%) control patients who died of renal failure. Multivariate analysis revealed age, serum creatinine at randomization and treatment with PTX as independent factors associated with survival. Our group currently uses PTX in patients with alcoholic hepatitis and with alcoholic cirrhosis because of its anti-inflammatory properties, its protective effects against hepatorenal syndrome and its excellent safety profile.
Silymarin (milk thistle)
Silymarin is probably the most widely used form of complementary and alternative medicine (CAM) in the treatment of liver disease in the USA. It has anti-oxidant activities, it protects against lipid peroxidation and it has anti-inflammatory and antifibrotic effects. Large controlled trials of Silymarin have been performed in Europe, with varying results. Ferenci et al 134 evaluated 170 patients with cirrhosis in a treatment programme (140 mg t.i.d.) having a mean duration of 41 months. They observed a positive beneficial effect, especially in patients with alcoholic cirrhosis and in those with milder disease (Child's A category). However, a study by Pares et al 135 found no beneficial effects (150 mg silymarin t.i.d.) in a study of 200 patients with alcoholic cirrhosis, some of whom also had hepatitis C. Both of these trials had major shortcomings, including high drop-out rates and compliance issues. In all studies performed thus far, the drug appears to be quite safe.
S-Adenosylmethionine
S-Adenosylmethionine (SAMe or AdoMet), is an obligatory intermediate in the conversion of methionine to cysteine in the hepatic trans-sulphuration pathway. SAMe is a precursor for the synthesis of polyamines, choline and glutathione (GSH) and it is the major methylating agent for a vast number of molecules via specific methyltransferases. 136 Patients with ALD have elevated plasma methionine levels, markedly delayed clearance of an oral methionine load and decreased hepatic methionine adenosyltransferase (MAT) activity (the enzyme responsible for conversion of methionine to SAMe). Hepatic-specific MAT is highly sensitive to oxidative stress and it is likely that the subnormal hepatic MAT activity reported in ALD is due to oxidation of the active site.
137 Studies from our laboratories have shown that SAMe downregulates production of the cytotoxic pro-inflammatory cytokine, TNF, in animal models of liver injury and in peripheral blood monocytes or macrophage cell lines in vitro. 138, 139 Mato et al 140 recently reported that patients with alcoholic liver cirrhosis who were randomized to receive SAMe (1200 mg/day orally) for 2 years had decreased liver mortality/liver transplantation (16% versus 30%) compared to the placebo treated group.
Antioxidants
Vitamin E. Vitamin E deficiency has been well documented in ALD. 141 Vitamin E has been used extensively with hepatoprotective effects in experimental models of liver injury such as that induced by carbon tetrachloride or ischaemia. Vitamin E has multiple potential beneficial effects including membrane stabilization 142 , reduced NFkB activation and TNF production 143 , and inhibition of hepatic stellate cell activation and collagen production. 144 Unfortunately, the major randomized study of vitamin E in ALD showed no benefit and probably used an inadequate dose (500 mg). 145 Glutathione prodrugs. GSH is a tripeptide that is synthesized from glutamate, cysteine and glycine. Glutathione prodrugs have been used extensively in virtually every known experimental model of hepatotoxicity with beneficial results. 146 The glutathione prodrug, N-acetylcysteine (given as Mucomyst), is the standard therapy for acetaminophen toxicity in humans. Maintaining adequate hepatocyte GSH levels has been documented to prevent acetaminophen liver injury. GSH prodrugs can directly affect the hepatocyte, and they can also positively modulate proinflammatory cytokine production with inhibition of cytokines such as TNF and IL-8. 143 Pena et al 147 demonstrated that the GSH prodrug, Procysteine, can increase whole blood GSH and inhibit monocyte TNF and IL-8 production when given intravenously to stable alcoholic cirrhotics. Similarly, Procysteine was shown to protect against alcohol-induced liver injury in the intragastric ethanol feeding model. 148 However, large, randomized studies of GSH prodrugs using mortality as an outcome indicator are lacking in ALD. Dilinoleoylphosphatidylcholine. Dilinoleoylphosphatidylcholine (a form of lecithin/soybean extract) has antioxidant, anti-fibrotic and anti-cytokine activity in experimental rat models of ALD. 149 However, a recently completed VA Cooperative Study failed to show significant benefit in human ALD.
The role of liver transplantation
There have been multiple recent studies and reviews concerning liver transplantation in patients with severe alcoholic cirrhosis. 150 -154 There is a well-documented organ shortage for liver transplantation and there are serious ethical issues concerning this controversial area that have precipitated these studies. Hepatitis C and ALD are the two major reasons for liver transplantation in the USA. Data clearly demonstrate that patients transplanted for ALD do (short-and long-term) as well as patients transplanted for hepatitis C or other types of liver disease. However, alcoholic hepatitis clearly is not an indication for liver transplantation at the current time. Virtually all centres require that alcoholic patients undergo formal psychiatric evaluation and treatment prior to transplantation. Many centres impose a 'six month rule' of abstinence before being considered for orthotopic liver transplantation (OLT); however, most centres also show some flexibility with this rule. It is unusual for ALD alone to be the cause of graft failure. The majority of patients with ALD are not listed for liver transplantation for multiple reasons including continued alcohol consumption, improvement of liver function with abstinence, lack of interest, etc. Patients with ALD appear to have a higher incidence of certain malignancies of the upper airway and upper digestive tract. Therefore, these patients should be screened for these processes prior to transplantation and monitored carefully post-transplantation. Data suggest that, following transplantation, patients who had ALD and those who were transplanted for other reasons consume alcohol at relatively similar rates, although those who had ALD may consume greater amounts. The rate of alcohol use increases over time for all transplant recipients. Some centres use multi-stage screening processes with risk stratification to select patients with low rates of recidivism. Clearly, more studies are required to refine our predictive capabilities for both recidivism and non-compliance. Quality of life appears to improve after liver transplantation due to any aetiology, although those with non-alcohol related aetiologies may improve more.
CONCLUSIONS
In summary, all patients should stop or markedly decrease alcohol intake and employ other lifestyle modifications where appropriate (Table 1) . Proper nutrition and nutritional support have consistently been shown to be important. Certain drugs (e.g. corticosteroids or pentoxifylline) may be effective in selected patients. While no FDAapproved therapies are available, many new agents, such as anti-TNF antibody, are under investigation. Transplantation is life-saving in certain abstinent patients with endstage liver disease.
Complications of ALD are important events in more advanced liver disease. Diagnosing and appropriately treating complications is vital for maintaining quality of life and decreasing morbidity and mortality. Some major complications include: (i) ascites, (ii) spontaneous bacterial peritonitis, (iii) hepatorenal syndrome, (iv) hepatic encephalopathy and (v) oesophageal varices. Various therapies can attenuate or reverse these complications but are often only palliative. Liver transplantation is curative. A discussion of these complications is beyond the scope of this chapter. However, the reader is directed to the following references, which review these important topics. 155 -161 
